Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone

European Neuropsychopharmacology

Volumn 20, Issue 12, 2010, Pages 829-838

  Crocq, M A ^a   Naber, D ^b   Lader, M H ^c   Thibaut, F ^d   Drici, M ^e   Everitt, B ^c   Hall, G C ^f   Le Jeunne, C ^g   Mittoux, A ^h   Peuskens, J ⁱ   Priori, S ^j   Sturkenboom, M ^k   Thomas, S H L ^l   Tanghoj P ^h   Toumi, M ^m   Mann, R ⁿ   Moore, N D ^o  

^a Centre Hospitalier de Rouffach   (France)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HÔPITAL CHARLES NICOLLE   (France)

^e PASTEUR HOSPITAL   (France)

^f Grimsdyke House   (United Kingdom)

^g HÔTEL DIEU   (France)

^h H LUNDBECK A S   (Denmark)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j UNIVERSITY OF PAVIA   (Italy)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m UNIVERSITÉ LYON 1   (France)

ⁿ CHU de Bordeaux Pellegrin ^*  (United Kingdom)

^o HÔPITAL PELLEGRIN   (France)

more..

Author keywords

Risperidone; ; Schizophrenia; ; Sertindole; Suicide attempt; ; Suicide;

Indexed keywords

RISPERIDONE; SERTINDOLE;

ADULT; AGED; ALGORITHM; ARTICLE; AUTOMUTILATION; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SUICIDE ATTEMPT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SINGLE-BLIND METHOD; SUICIDE; SUICIDE, ATTEMPTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77958198145     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.09.001     Document Type: Article

References (57)

1. Aguilar E.J., Siris S.G. Do antipsychotic drugs influence suicidal behavior in schizophrenia?. Psychopharmacol. Bull. 2007, 40:128-142.
2. Allgulander C., Allebeck P., Przybeck T.R., Rice J.P. Risk of suicide by psychiatric diagnosis in Stockholm County: a longitudinal study of 80,970 psychiatric inpatients. Eur. Arch. Psychiatry Clin. Neurosci. 1992, 241:323-326.
3. Altamura A.C., Bassetti R., Bignotti S., Pioli R., Mundo E. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr. Res. 2003, 60:47-55.
4. Azorin J.M., Murteira S., Hansen K., Toumi M. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis. BMC Psychiatry 2008, 8:16.
5. Bakst S., Rabinowitz J., Bromet E.J. Antecedents and patterns of suicide behavior in first-admission psychosis. Schizophr. Bull. 2010, 36:880-889.
6. Barak Y., Mirecki I., Knobler H.Y., Natan Z., Aizenberg D. Suicidality and second-generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology 2004, 175:215-219.
7. Beisser A.R., Blanchette J.E. A study of suicides in a mental hospital. Dis. Nerv. Syst. 1961, 22:365-369.
8. Bousquet C., Lagier G., Lillo-Le Louët A., Le Beller C., Venot A., Jaulent M.C. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf. 2005, 28:19-34.
9. Bray I., Gunnell D. Suicide rates, life satisfaction and happiness as markers for population mental health. Soc. Psychiatry Psychiatr. Epidemiol. 2006, 41:333-337.
10. Breier A., Astrachan B.M. Characterization of schizophrenic patients who commit suicide. Am. J. Psychiatry 1984, 141:206-209.
11. Caldwell C.B., Gottesman I.I. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr. Bull. 1990, 16:571-588.
12. De Hert M., McKenzie K., Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr. Res. 2001, 47:127-134.
13. Evans J., Middleton N., Gunnell D. Social fragmentation, severe mental illness and suicide. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39:165-170.
14. Harkavy-Friedman J.M., Nelson E.A., Venarde D.F. Suicidal behavior in schizophrenia and schizoaffective disorder. Clin. Neurosci. Res. 2001, 1:345-350.
15. Haukka J., Tiihonen J., Härkänen T., Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol. Drug Saf. 2008, 17:686-696.
16. Heila H., Isometsa E.T., Henriksson M.M., Heikkinen M.E., Marttunen M.J., Lönnqvist J.K. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am. J. Psychiatry 1997, 154:1235-1242.
17. Heilä H., Haukka J., Suvisaari J., Lönnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol. Med. 2005, 35:725-732.
18. Helgason L. Twenty years' follow-up of first psychiatric presentation: what could have been prevented?. Acta Psychiatr. Scand. 1990, 81:231-235.
19. Johnson D.A., Pasterski G., Ludlow J.M., Street K., Taylor R.D. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr. Scand. 1983, 67:339-352.
20. Kerwin R.W., Bolonna A.A. Is clozapine antisuicidal?. Expert Rev. Neurother. 2004, 4:187-190.
21. Kreyenbuhl J.A., Kelly D.L., Conley R.R. Circumstances of suicide among individuals with schizophrenia. Schizophr. Res. 2002, 58:253-261.
22. Levine S.Z., Bakst S., Rabinowitz J. Suicide attempts at the time of first admission and during early course schizophrenia: a population based study. Psychiatry Res. 2010, 177:55-59.
23. Mamo D.C. Managing suicidality in schizophrenia. Can. J. Psychiatry 2007, 52(6 Suppl 1):59S-70S.
24. Meltzer H.Y. Treatment of suicidality in schizophrenia. Ann. NY Acad. Sci. 2001, 932:44-60.
25. Meltzer H.Y., Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin. Neuropharmacol. 1995, 18(Suppl. 3):S18-S24.
26. Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 1995, 152:183-190.
27. Meltzer H.Y., Alphs L., Green A., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.-P., Potkin S. Clozapine treatment for suicidality in schizophrenia. Arch. Gen. Psychiatry 2003, 60:82-91.
28. Miles C.P. Conditions predisposing to suicide: a review. J. Nerv. Ment. Dis. 1977, 164:231-246.
29. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am. J. Psychiatry 2007, 164:630-637.
30. Montout C., Casadebaig F., Lagnaoui R., Verdoux H., Philippe A., Begaud B., Moore N. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr. Res. 2002, 57:147-156.
31. Mortensen P.B., Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br. J. Psychiatry 1993, 163:183-189.
32. Nangle J.M., Clarke S., Morris D.W., Schwaiger S., McGhee K.A., Kenny N., Murphy K., Gill M., Corvin A., Donohoe G. Neurocognition and suicidal behaviour in an Irish population with major psychotic disorders. Schizophr. Res. 2006, 85:196-200.
33. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record-linkage study. Can. J. Psychiatry 1991, 36:239-245.
34. Nyberg S., Olsson H., Nilsson U., Maehlum E., Halldin C., Farde L. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 2002, 162:37-41.
35. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr. Res. 2000, 45:21-28.
36. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia. A reexamination. Arch. Gen. Psychiatry 2005, 62:247-253.
37. Peuskens J., Tanghø j.P., Mittoux A. Sertindole Cohort. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol. Drug Saf. 2008, 17:425-433.
38. Pompili M., Amador X.F., Girardi P., Harkavy-Friedman J., Harrow M., Kaplan K., Krausz M., Lester D., Meltzer H.Y., Modestin J., Montross L.P., Mortensen P.B., Munk-Jørgensen P., Nielsen J., Nordentoft M., Saarinen P.I., Zisook S., Wilson S.T., Tatarelli R. Suicide risk in schizophrenia: learning from the past to change the future. Ann. Gen. Psychiatry. 2007, 6:10.
39. Pompili M., Lester D., Grissini A., Innamorati M., Calandro F., Iliceto P., De Pisa E., Tatarelli R., Girardi P. Completed suicide in schizophrenia: evidence from a case-control study. Schizophr. Res. 2009, 167:251-257.
40. Posner K., Oquendo M.A., Gould M., Stanley B., Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am. J. Psychiatry 2007, 164:1035-1043.
41. Qin P.N., Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch. Gen. Psychiatry 2005, 62:427-432.
42. Reutfors J., Brandt L., Jönsson E.G., Ekbom A., Sparén P., Ösby U. Risk factors for suicide in schizophrenia: findings from a Swedish population-based case-control study. Schizophr. Res. 2009, 108:231-237.
43. Rossau C.D., Mortensen P.B. Risk factors for suicide in patients with schizophrenia: nested case-control study. Br. J. Psychiatry 1997, 171:355-359.
44. Roy A. Suicide in chronic schizophrenia. Br. J. Psychiatry 1982, 141:171-177.
45. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx. 2005, 2:590-611.
46. Schennach-Wolff R., Jäger M., Seemüller F., Obermeier M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Maier W., Lemke M.R., Rüther E., Klingberg S., Gastpar M., Möller H.J., Riedel M. Outcome of patients with schizophrenia: results from a naturalistic study. Acta Psychiatr. Scand. 2010, 121:359-370.
47. Sernyak M.J., Desai R., Stolar M., Rosenheck R. Impact of clozapine on completed suicide. Am. J. Psychiatry 2001, 158:931-937.
48. Siris S.G. Suicide and schizophrenia. J. Psychopharmacol. 2001, 15:127-135.
49. Spivak B., Mester R., Wittenberg N., Maman Z., Weizman A. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin. Neuropharmacol. 1997, 20:442-446.
50. Svenningsson P., Tzavara E.T., Qi H., Carruthers R., Witkin J.M., Nomikos G.G., Greengard P. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J. Neurosci. 2007, 27:4201-4209.
51. Thomas S.H.L., Drici M.D., Hall G.C., Crocq M.A., Everitt B., Lader M.H., Jeunne C.L., Naber D., Priori S., Sturkenboom M., Thibaut F., Peuskens J., Mittoux A., Tanghøj P., Toumi M., Moore N.D., Mann R.D. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr. Scand. 2010, April 8. [Epub ahead of print].
52. Tiihonen J., Walhbeck K., Lönnqvist J., Klaukka T., Ioannidis J.P., Volavka J., Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br. Med. J. 2006, 333:224-229.
53. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
54. Trémeau F., Staner L., Duval F., Corrêa H., Crocq M.A., Darreye A., Czobor P., Dessoubrais C., Macher J.P. Suicide attempts and family history of suicide in three psychiatric populations. Suicide Life Threat Behav. 2005, 35:702-713.
55. Walker A.M., Lanza L.L., Arellano F., Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 1997, 8:671-677.
56. Wesołowska A., Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 2007, 52:1274-1283.
57. The ICD-10 classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines 1992, World Health Organization, World Health Organization, Geneva.